ten23 health expands Swiss sterile drug product manufacturing site
The FDA-inspected site in Visp, which was acquired last October as part of ten23 health’s acquisition of swissfillon, offers sterile manufacturing of pre-filled syringes, vials, and cartridges for clinical trial and market supplies.
To enable further growth of its existing production capacity, ten23 health is investing in an expansion of supporting areas in an adjacent building. This expansion will provide an additional 1000 square meters of clean-room space for visual inspection and cold storage and also include clean-room space for additional services, such as supporting device assembly operations and labeling and secondary packaging.
Prof. Dr. Hanns-Christian Mahler, CEO of ten23 health, said: “Only five months ago, swissfillon joined ten23 health. This first expansion of the footprint in Visp is a strong commitment to our location in the Valais as well as Switzerland and a testimonial of the competent and experienced team at Visp. Furthermore, it is an important step in our long-term strategy to expand our manufacturing capacity for complex sterile dosage forms for our customers and their patients.”
ten23 health’s combination of pharmaceutical development services with clinical and commercial fill & finish services offers clients an end-to-end set of capabilities. ten23 health launched its operations in Basel, Switzerland, in September 2021, with 4000 square meters of lab and office space, providing a work environment for up to 150 colleagues.
The company acquired swissfillon, which focuses on the sterile filling of complex pharmaceuticals, eying up ‘expected significant growth’ in the coming years in sterile fill and finish services. This is being driven by expanded drug development pipelines, incorporating more complex, large molecule products and therapies.